1B50-1 (Peking University Health Science Center/Beijing Cancer Hospital)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Name1B50-1 (Peking University Health Science Center/Beijing Cancer Hospital)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionVoltage-gated calcium channel alpha2/delta subunit 1 blockers
TargetsVoltage-gated calcium channel alpha2/delta subunit 1
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesPeking University Health Science Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeijing Cancer HospitalPeking University Health Science Center
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A